Data from up to 42 months of treatment reinforce lucerastat’s potential as a first-in-class oral substrate reduction therapy addressing key unmet needs across the Fabry populationThe company is ...
Bacteria can be turned into living factories that churn out complex molecules using reactions catalysed by light 1.
Colorectal cancer is one of the most prevalent tumors and a leading cause of cancer-related mortality. Despite advances achieved in recent years, resistance to available treatments remains one of the ...
Amicus Therapeutics (Nasdaq: FOLD), today announced the presentation of new data from clinical and real-world studies of Galafold® (migalastat) in Fabry disease and POMBILITI® + OPFOLDA® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results